Printer Friendly


 KANSAS CITY, Mo., Sept. 21 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) today announced plans for a transition in senior management, which includes the following changes, all effective on Jan. 1, 1994:
 -- Joseph G. Temple, Jr., 64, chairman of the board, will step down from that position but will remain a member of the board of directors of both Marion Merrell Dow and The Dow Chemical Co. Beyond the end of the year, Temple will serve Marion Merrell Dow as a consultant to management.
 -- Fred W. Lyons, Jr., 57, president and chief executive officer of Marion Merrell Dow, will assume the position of chairman of the board and will continue as chief executive officer.
 -- David B. Sharrock, 57, executive vice president and chief operating officer, will retire after 35 years with Marion Merrell Dow and its predecessor companies. He also will remain on the company's board of directors and serve as a consultant to management.
 -- Richard J. Markham, 42, former president and chief operating officer of Merck & Co. Inc., will join Marion Merrell Dow as president and chief operating officer. He has been nominated to become a member of the board of directors at its November meeting.
 Temple commented on the transition: "As I cease to be Marion Merrell Dow's chairman, I am very pleased and excited to leave this company in the capable hands of Fred Lyons and his staff -- and to see Dick Markham, one of the industry's most dynamic young leaders, joining the management team."
 Temple has been chairman of the board of Marion Merrell Dow since its creation in December 1989 and was chief executive officer from 1989 to 1992, when Lyons assumed that position. Temple joined The Dow Chemical Co. in 1951 and progressed through the management ranks to the level of executive vice president. In 1981, he was named president and chief executive officer of Merrell Dow Pharmaceuticals Inc., a Dow subsidiary that merged with Marion Laboratories Inc., in 1989 to become Marion Merrell Dow. He is a graduate in chemical engineering of Purdue University and holds an honorary doctorate from Purdue.
 Lyons has been president of Marion Merrell Dow since December 1989 and chief executive officer since Jan. 1, 1992. He joined Marion Laboratories in 1970 as vice president and general manager and served in several capacities before being named president in 1977 and chief executive officer of Marion in 1984. He is a graduate of the University of Michigan College of Pharmacy and holds a master of business administration degree from Harvard University as well as an Honorary Degree of Humane Letters awarded by Long Island University.
 Markham, who resigned as president and chief operating officer of Merck & Co. in July 1993, will join Marion Merrell Dow by Oct. 1, 1993, and will work with Sharrock to ensure a smooth transition in leadership for global operations. Markham began his career in 1973 as a professional representative with Merck and advanced through sales and marketing management. From 1989 to 1991, he was a senior vice president responsible for Merck's European business. In 1991 and 1992, he was senior vice president of Merck & Co. and president of the Merck Human Health Division, responsible for worldwide marketing and sales. He is a pharmacy graduate of Purdue University.
 "We feel quite fortunate to bring in a leader of Dick Markham's caliber at a time when Marion Merrell Dow and the entire health care field are going through dramatic changes. Dick is dynamic, innovative and very much in touch with the changing needs of customers in the global pharmaceutical industry," Lyons said. "It is these attributes that make him the right person to help lead Marion Merrell Dow to success in a new era of health care."
 Sharrock has managed Marion Merrell Dow's global operations since 1989 as executive vice president and chief operating officer. He began his career in 1958 with the Merrell division of Richardson-Merrell Pharmaceuticals, a predecessor company to Marion Merrell Dow, served in various sales and marketing positions, and then advanced through several management positions to become president and chief operating officer of Merrell Dow Pharmaceuticals in 1988. He was named executive vice president and chief operating officer of Marion Merrell Dow at the time of the company's creation in 1989.
 "Dave Sharrock's retirement culminates a highly successful career as a leader for our company and the pharmaceutical industry," Temple said. "He has played a central role in Marion Merrell Dow's evolution and growth and has dedicated himself consistently to the success of the company and its associates. The experience of working together with him for over 10 years has been extremely rewarding. Dave has indicated a desire to retire and pursue personal interests for some time, but we are delighted that we will continue to benefit from his experience and wisdom as a member of our board."
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide.
 -0- 9/21/93
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/

CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU: PER

MC -- DV003 -- 4160 09/21/93 12:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 21, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters